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Abstract
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding
specificities for two different antigens, which may provide additive or synergistic modes of action. There is a wide variety of
design alternatives for such bispecific antibodies, including the ‘‘CrossMab’’ format. CrossMabs contain a domain crossover
in one of the antigen-binding (Fab) parts, together with the ‘‘knobs-and-holes’’ approach, to enforce the correct assembly of
four different polypeptide chains into an IgG-like bispecific antibody. We determined the crystal structure of a hAng-2-
binding Fab in its crossed and uncrossed form and show that CH1-CL-domain crossover does not induce significant
perturbations of the structure and has no detectable influence on target binding.
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Introduction
Therapeutic antibodies are used to treat a multitude of human
diseases. They can routinely be obtained by mature technologies
such as immunization or in-vitro display approaches. The natural
variability of complimentarity-determining regions (CDRs) allows
for the discovery of specific, high-affinity antibodies. Most of these
therapeutic antibodies have the Immunoglobulin G (IgG) format
which confers long serum half-life due to an FcRn-mediated
recycling mechanism. In contrast to monospecific antibodies,
bispecific antibodies offer additional features which cannot be
accomplished otherwise, e.g. the selective targeting of a cell
population characterized by two targets to improve safety and/or
efficacy [1] [2].
A typical IgG antibody consists of two identical heavy chains
(HCs) and two identical light chains (LCs) [3]. The N-terminal,
antigen-binding domains of HCs and LCs are variable in sequence
and are called VH and VL [4]. Typical IgG-type antibodies
comprise two identical antigen-binding arms (Fabs), and an
effector domain, Fc. Each Fab contains one light chain and heavy
chain (reviewed by [5]).
The homodimerization of two HCs is achieved by strong non-
covalent, predominantly hydrophobic interactions in the CH3-
CH3 domain interface. In addition, HC homodimerization is
stabilized by disulfide bridges in the lower hinge region. Unlike the
CH3 domains, the CH2 domains are not involved in dimerization.
Practically no protein contacts exist between the two CH2 domains
of an IgG, but N-linked carbohydrates fill the intervening space.
Instead, CH2 domains are responsible for the interaction with Fcc
receptors and the complement protein C1q [6].
Noteworthy, antibodies of the IgG4 subtype rapidly exchange
half antibodies both in vitro and in vivo because the IgG4 hinge
region allows for disulfide scrambling which breaks the covalent
bonds between two HCs under redox-promoting conditions.
Additionally, the CH3-CH3 domain interface provides weaker
non-covalent contacts than in other IgG subtypes [7,8].
The covalent HC-LC heterodimerization is achieved by a
disulfide bridge between the CH1 and CL domains. Additionally,
strong non-covalent interactions between the VH and VL domains,
and between the CH1 and CL domains, respectively, enforce HC-
LC pairing. The strength of VH and VL domain interaction, as
well as the stability of the resulting VHVL pair is influenced by
germline family (reviewed in [9]) and CDR sequences [10]. Albeit
HCs of any VH germline family can stably interact with LCs of
any VL germline family, the exact factors that govern the stability
of VH and VL domain interaction seem to be complex and still lack
a mechanistic understanding [9–12]. The free CH1 domain is
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intrinsically disordered and was found to be stabilized by the
interaction with the CL domain. A molecular chaperone, BiP,
binds to incompletely folded CH1 domains before it is replaced by
the CL domain. Additionally, a conserved proline residue under-
goes isomerization during the CH1 folding process [13].
In vivo, every antibody-producing cell (e.g. B-cell) produces only
one sort of antibody at a given time. Therefore there was no
evolutionary necessity for preferential HC-LC association within a
mixture of HCs and LCs. Consequently, co-expression of two
different HCs and two different LCs, i.e. the constituents of two
different antibodies, as observed in the ‘‘quadroma approach’’,
leads to a stochastic mixture of 10 different antibodies, in which
the desired bispecific antibody is expected only in low amounts
([14,15] and Figure S10 in [16]). Heterodimeric HC association
can be achieved with high selectivity by the knobs-into-holes
approach [17–20]. Here, residues in the CH3-CH3 interface are
replaced by different residues in either heavy chain so that an
asymmetric, mutually exclusive dimerization interface is formed.
Heterodimers can be additionally stabilized by a disulfide bridge in
the CH3 domain which is designed to form in heterodimers but not
in homodimers.
Such HC heterodimers still associate with two different LCs in a
non-selective way. One way to bypass this challenge is the use of a
‘‘common light chain’’ which is selected to provide – in
combination with either of the HCs – high affinity binding to
two different targets [21]. Creating selective, high-affinity
antibodies sharing a common light chain however requires specific
antibody generation approaches (e.g. by phage display) and is not
readily applicable for the combination of two existing antibodies
into a bispecific antibody.
A generic approach to assemble two different heavy and two
different light chains into a bivalent, bispecific IgG antibody
(‘‘CrossMab’’) without artificial linkers was recently reported [16].
Correct pairing of two different LCs with their respective HCs is
achieved by a CH1-CL-domain crossover in one of the Fabs
(Figure 1A). In contrast to other approaches to generate bispecific
IgG-like antibodies (e.g. reviewed in [1]), any existing pair of
monoclonal antibodies can be combined into a CrossMab. This
approach is based on the assumption that the overall structure of
such a CrossMab closely resembles a normal IgG and that the Fab
domains are not significantly altered compared to their uncrossed
counterparts.
To reveal potential structural effects of the crossover procedure
on the resulting bispecific antibodies, we report the crystal
structure of a human Angiopoietin 2 (hAng2) binding ‘‘CrossFab’’,
i.e. a Fab derivative in which the VL domain is fused to the CH1
domain, while the VH domain is fused to the CL domain (‘‘CH1-
CL crossover’’ in [16]). For comparison, we also determined the
crystal structure of the corresponding ‘‘uncrossed’’ Fab. Both
structures show a high degree of similarity in the variable and
constant domains. However, marked differences in their elbow
angles (i.e. the angle between VHVL and CH1CL domains, see
Materials and Methods) are observed, which do not influence
target binding.
Results
CrossFab design
The original, uncrossed Ang2-binding Fab was obtained by
phage display of a scFv library and belonged to the IgG1l
subgroup. The uncrossed Fab was generated by adding constant
domains CH1 and a CL domain of the kappa subtype, which is the
more frequently occurring light chain subtype in therapeutic
antibodies.
For the design of the elbow crossing points, the X-ray structure
3NPS [22] was selected as a template because both chains of this
Fab exhibit a high degree of homology with the anti-Ang2 Fab
chains. In addition, both molecules possess a l variable and a k
constant domain, and thus contain almost identical elbow
sequences (Figure 1B).
Selection of the elbow crossing points aimed at maximal
preservation of the native elbow structure, together with maximum
sequence conservation to the native elbow sequences. Thus,
structurally homologous elbow residues in the LC and the HC
were identified by a structure-guided alignment of CH1 with CL
sequences, including the elbow regions, using the structure 3NPS
as a template. Since the lengths of the HC and LC elbow
sequences differ by one amino acid, the longer alternative was
chosen on both the crossed LC and the crossed HC to avoid steric
constraints. Extra care was taken to preserve the orientation of the
side chain vectors Ca-Cb in the crossed elbow region. A high
degree of local sequence homology between the VH-CH1 and VL-
CL elbow regions allows construction of crossed elbow regions with
a minimum number of non-conservative mutations.
An automated algorithm to detect potential T-cell epitopes did
not show any alerts for the heavy chain-light chain transition
sequences [23]. For purification and assay purposes, the Fab and
CrossFab were expressed with a C-terminal Avi-His tag. Beside
the CH1-CL domain exchange, there are no further differences
between the Fab and the CrossFab sequences.
Crystal Structure
The crystal structures of Fab and CrossFab, determined at a
resolution of 2.2 and 2.9 A˚, respectively, exhibit, as expected, the
typical Fab geometry (Figure 2A). Although the diffraction data
quality and hence the obtained resolution is slightly lower in the
CrossFab (Table 1), the resulting electron density allowed
unambiguous model building. The molecule regions directly
affected by the CrossFab design, i.e. the elbow and adjacent
regions, show clear electron density in unbiased composite omit
Figure 1. CrossMab design. (A) Schematic representation of the
domain crossover leading to CrossFabs. Right: Combination of a Fab
and a CrossFab to obtain a CrossMab [16]. Antibody domains are
symbolized as ovals. Light colors are used for LC domains; darker colors
are used for HC domains. This color code is used throughout. (B)
Sequence alignment of the elbow and adjacent regions of LC and HC in
Fab and CrossFab.
doi:10.1371/journal.pone.0061953.g001
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maps, indicating a defined geometry and low flexibility (Figure 2D).
The structural differences are most pronounced in loop regions
(e.g. CDR 3 loops, Figure 2B) that intrinsically allow for a certain
degree of flexibility in the absence of a bound antigen. A potential
reason for the conformational difference between the heavy chain
CDR3 loops from crystal structures of Fab and CrossFab may be
the different role of this flexible loop element in mediating crystal-
packing contacts in both structures. Nonetheless, the overall
domain structure within the framework regions is very similar
between Fab and CrossFab. A superposition of the VH and VL
domains of Fab and CrossFab show a root mean square deviation
(rmsd) of 0.43 A˚ (Ca atoms only, excluding CDR H3) (Figure 2B).
The CH1 and CL domains can be superimposed with an rmsd of
the Ca atoms of 0.40 A˚ (Figure 2C), demonstrating the high
structural similarity between the Fab and the CrossFab. The slight
differences between domain structures of identical sequences in
Fab and CrossFab may be explained by the different crystal
packing, although both Fabs crystallized in space group P212121.
The CrossFab structure shows clear electron density in the
elbow region (Figure 2D), indicating that these engineered
portions of the CrossFab are well-ordered. A striking difference
of the Fab and CrossFab structures lies in the elbow angle, i.e. the
angle between VHVL and CH1CL domains. The two molecules in
the asymmetric unit of the Fab structure exhibit elbow angles of
138 and 145 degrees, respectively, whereas the CrossFab
molecules in the asymmetric unit show 163 and 167 degrees,
respectively. Like above, these differences may originate from
differential crystal packing which may enforce distinct angles
between the rather flexibly connected domains, although the
artificial linker in the crossover procedure could have direct
influence on the elbow angles or at least the conformational
spectrum. A study of the distribution of elbow angles in
experimental X-ray structures shows that possible elbow angles
cover a wide range (127 to 220 degrees in the reported set of
examples) [24]. Both elbow angles of the Fab and the CrossFab fall
within this range (Figure 3A). To compare the overall structure of
the CrossFab to published Fab structures, we used the "topsearch"
program [25]. The closest match (PDB code 3FMG), was
superimposed on the CrossFab (Figure 3B). It can clearly be seen
that the domain orientation encountered in the CrossFab,
especially the elbow angle, falls in the range exhibited by Fabs
with natural domain organization. Most importantly, although
one of the elbow chains contains one amino acid more than a
native Fab, this does not cause a tilt between VHVL and CH1CL
domains (Figure 3C). In summary, the structural analysis shows
Figure 2. Crystal structures and electron density maps. (A) Comparison of the Fab and CrossFab structures side-by-side. Residues involved in
hydrogen bonds between the constant and the variable domains are shown as sticks and hydrogen bonds are shown as red dashed lines. The color
code used is as in Figure 1. (B) Superposition of variable domains in Fab and CrossFab. C-alpha atoms excluding CDR H3 were used. Fab and CrossFab
variable domains superimpose with an rmsd of 0.43 A˚. (C) Superposition of the constant domains in Fab and CrossFab using C-alpha atoms. Fab and
CrossFab constant domains superimpose with an rmsd of 0.40 A˚. (D) Composite omit maps around the VHVL-CH1CL interface of the CrossFab and the
Fab, contoured at 1.0 sigma using a carve distance of 2.0 A˚.
doi:10.1371/journal.pone.0061953.g002
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that the crossover procedure does result in a Fab that falls into the
structural spectrum exhibited by the natural domain organization.
Function and stability
To see whether CrossFab has target binding properties different
from the uncrossed Fab we determined binding kinetics and
affinity of the Fab and the CrossFab to their target, hAng2, by
surface plasmon resonance. The measured affinities were
35.560.09 nM and 37.062.6 nM, respectively. Moreover, no
significant difference in the kinetic parameters kon and koff was
found, indicating that the structural features relevant for target
binding are maintained in the CrossFab (Figure 4A).
Thermal stability of Fab and CrossFab was measured by
temperature dependent intrinsic fluorescence since protein dena-
turation leads to a shift of the fluorescence emission maximum.
Melting temperatures of 71uC and 66 uC were measured for the
Fab and the CrossFab, respectively. (Figure 4B). The lower
thermal stability of the CrossFab might be attributed to fewer
stabilizing contacts between the variable and the constant domains
in the CrossFab compared to the Fab. In essence, there are three
pairs of residues forming hydrogen bonds between the VL and CL
domains in the Fab but none such interactions were found in the
CrossFab (Figure 2A). Nonetheless, the measured thermal stability
of both Fab and CrossFab can be regarded as comparatively high
[11], indicating no major structural perturbations.
Table 1. Data collection and refinement statistics.
CrossFab Fab
Data collection
Space group P212121 P212121
Cell dimensions
a, b, c (A˚) 75.6, 80.6, 158.3 66.0, 86.7, 205.8
a, b, c (u) 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution (A˚) 45.26–2.93 (3.10–2.93)* 47.55–2.20 (2.33–2.20)
Rsym (%)
$ 17.3 (78.2) 4.1 (75.0)*
I/sI 8.54 (2.09) 25.89 (2.72)
Completeness (%) 98.4 (90.4) 99.8 (98.8)
Redundancy 6.3 (6.0) 6.6 (6.7)
Refinement
Resolution (A˚) 44.10–2.93 46.76–2.20
No. reflections 21156 60561
Rwork/Rfree (%) 23.7/26.9 20.0/22.6
No. atoms
Protein 6724 6688
Ligand 12 18
Water 7 319
Average B-Factor 71.40 53.39
R.m.s. deviations:
Bond lengths (A˚) 0.003 0.004
Bond angles (u) 0.863 0.805
*Values in parentheses are for the highest-resolution shell.
$Rsym~
P
j I hð Þj j{vI hð Þw =
P
j I hð Þ



j
, where I hð Þj is the scaled observed
intensity of the jth observation of reflection h, andvI hð Þwis the mean value of
corresponding symmetry-related reflections.
doi:10.1371/journal.pone.0061953.t001
Figure 3. Elbow angles and relative domain orientation. (A)
Superposition of Fab and CrossFab with example structures covering
the range of observed elbow angles. Example structures (shown as
loops), their orientations and color coding are according to Figure 1 in
[24]. All structures are superimposed via their VL domains. The colors of
Fab and CrossFab are analogous to Figure 1. (B) Superposition of the
CrossFab with its closest structural homolog (PDB code 3FMG). (C)
Relative domain orientation of variable and constant domains in Fab
and CrossFab. The pseudo-twofold axes of variable and constant
domains are shown as light and dark purple dumbbells, respectively.
Molecules are oriented so that the axes connecting the last Fv residues’
C-alpha atoms, as well as the Fv pseudo-twofold axis are parallel to the
paper plane. An asterisk marks the VL-CH1 junction, which is two amino
acids longer than the corresponding VL-CL junction.
doi:10.1371/journal.pone.0061953.g003
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Discussion
In this report, we analyzed whether and to what extend the
CrossMab design to generate bi-specific antibodies affects
structural and target-binding properties of the crossed Fab region
in comparison with the non-crossed parent Fab. CrossMabCH1CL
was shown to be expressed in eukaryotic cells with high fidelity
concerning the correct HC-LC association [16]. This indicates a
high degree of selectivity that originates both from the knobs-into-
holes approach and the HC-LC crossover. In a CrossMab
combining a crossed and an uncrossed Fab, all incorrect chain
associations (e.g. an uncrossed HC with a crossed LC) involve
domain contacts that are non-binding or even repulsive. Thus,
sufficient selectivity is created to yield a relatively homogeneous
product profile [16].
Taken together, these functional and structural data demon-
strate the modularity of the immunoglobulin superfamily as
applied to human antibodies. The data indicate that the CrossMab
approach retains the structure of its parental antibodies and as
such most if not all of their functional properties, thereby making it
a generic approach that can be applied to any antibody pair.
Because the CrossFab structure appears highly similar and
unperturbed compared to the parental Fab structure, this may –
together with the absence of any artificial linker sequences - be
beneficial for low immunogenicity in humans.
Amongst the CrossMab alternatives published (Cross-
MabCH1CL, CrossMabVHVL and CrossMabFab), the Cross-
MabCH1CL is preferred due to its theoretical side product profile
that was confirmed when the different CrossMabs were expressed
in parallel and analyzed for their side purity [16]. The approach
chosen and in particular the elbow region in the CrossMabCH1CL
allows correct chain association and generation of a functional
antibody as predicted. Based on our structural and biochemical
data we believe that the CrossMAb approach represents a viable
option for the generation of human bispecific heterodimeric IgG
antibodies of different isotypes.
Materials and Methods
Cloning, expression and purification of Fab and CrossFAb
Fab and CrossFab constructs were designed to bear a C-
terminal Avi-His6-tag at the CH1 domain. All genes were obtained
via gene synthesis and cloned via unique restriction sites using
standard cloning procedures. Every chain was part of a separate
expression vector enabling secretory expression in human
embryonic kidney (HEK) cells growing in suspension. Transfection
into HEK293-F cells (Invitrogen) was performed according to the
cell supplier’s instructions using Maxiprep (Qiagen) preparations
of the antibody vectors, Opti-MEMH I medium (Invitrogen, USA),
293fectinTM (Invitrogen, Germany) and an initial cell density of 1–
2 million viable cells/ml in serum free FreeStyle 293 expression
Figure 4. Target binding and thermal stability. (A) Surface plasmon resonance sensogram of the Fab and CrossFab interacting with their target,
hAng2. One out of three runs for the Fab and the CrossFab is shown. Coloured curves represent the measured data at various Fab or CrossFab
concentrations, while the result of the global fit to a 1:1 Langmuir model is illustrated by black curves. The table shows average values and standard
deviations derived from triplicate measurements (ka: association rate; kd: dissociation rate; KD: affinity). (B) Measurement of protein stability by
temperature-dependent protein autofluorescence emission maximum wavelength.
doi:10.1371/journal.pone.0061953.g004
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medium (Invitrogen). Cell culture supernatants were harvested
after 7 days of cultivation in shake flasks or stirred fermenters by
centrifugation at 14000 g for 30 minutes and filtered through a
0.22 mm filter.
Fab and CrossFab-containing supernatants were applied on a
HisTrap column (GE Healthcare), washed with 20 mM sodium
phosphate, 500 mM NaCl, 5 mM imidazole, pH 7.4 and eluted
with washing buffer supplemented with 500 mM imidazole.
Aggregated protein was removed by size exclusion chromatogra-
phy (Superdex 200, GE Healthcare) in 20 mM Histidine, 140 mM
NaCl pH 6.0. Monomeric protein fractions were pooled, concen-
trated if required using an Amicon Ultra (10 kD molecular weight
cutoff) centrifugal concentrator (Millipore) and stored at 280uC.
Purity was assessed to be .95% by SDS-PAGE and analytical
size-exclusion chromatography.
Cloning, expression and purification of hAng2
His-tagged full-length Ang2 was cloned by standard protocols
and transiently expressed in HEK cells. Ang2-containing super-
natant was applied to a HisTrap column (GE Healthcare)
equilibrated with 20 mM sodium dihydrogenphosphate,
500 mM NaCl pH 7.4, washed with equilibration buffer supple-
mented with 20 mM imidazole and eluted in 20 mM sodium
dihydrogenphosphate, 500 mM NaCl, 500 mM imidazole,
pH 7.4. Full-length Ang2-containing fractions were pooled and
dialysed against a 100-fold volume of dialysis buffer (20 mM Tris,
200 mM NaCl, 0.01% Tween 20, pH 7.5) overnight using slide-a-
lyser dialysis cassettes (Thermo Scientific).
Crystallization and structure determination
Prior to crystallization, both the Fab and the CrossFab were
freshly thawed and applied to a Superdex 200 26/60 pg size
exclusion column (GE Healthcare). Chromatography was per-
formed at 8 uC in 20 mM HEPES-HCl, pH 7.0 and 150 mM
NaCl for the Fab and in 20 mM Imidazole-HCl, pH 6.0 and
100 mM NaCl for the CrossFab. The peak fractions were pooled
and concentrated immediately prior to crystallisation setups to
11 mg/mL in case of the Fab and 17 mg/mL in case of the
crossed Fab using an Amicon Ultra (10 kD molecular weight
cutoff) centrifugal concentrator (Millipore).
Both proteins were crystallized by the hanging drop vapor
diffusion method at 20 uC. A volume of 1 ml of protein was mixed
with 1 ml of reservoir solution (15%(w/v) PEG4000, 0.1 M Tri-
Na-Citrate, 15%(v/v) Isopropanol in case of the Fab, and 17.5–
20%(w/v) PEG 6000, 0.1 M citric acid, 0.2 M NDSB-221,
pH 5.0, in case of the CrossFab). Crystals were cryoprotected by
soaking them for 30 seconds in mother liquor solution containing
20%(v/v) glycerol, and flash frozen in liquid nitrogen. Diffraction
data from single crystals were collected at 100 K at the beamline
PX I of the SLS (Villigen, Switzerland).
Data refinement and structure solution
Diffraction data were integrated and scaled with XDS [26] (see
Table 1 for data collection and refinement statistics). In case of the
CrossFab, the space group was determined by the program
‘‘pointless’’ [27] to be P212121, with two CrossFab molecules in the
asymmetric unit [28]. The structure of the CrossFab was solved by
molecular replacement with Phaser [29] using a polyalanine
search model which was generated from a homology model of the
CrossFab. The homology model itself was created using the
program modeller 9v7 [30]. A highly homologous Fab structure
(PDB code 3LMJ) was used as the modeling template. The final
structure of the CrossFab was generated by multiple cycles of
manual model building using COOT [31] followed by refinement
using phenix refine [32]. The final R-factors of the model are
Rwork = 23.7% and Rfree = 26.9%, respectively.
The structure of the uncrossed Fab was solved using Phaser [29]
with the cross Fab structure as a replacement model. The variable
domains and the constant domains were searched as separate
models in Phaser. The model was completed by manual model
building in the resulting electron density map using COOT [33].
The model was refined by iterative cycles of bulk solvent
correction, individual B-factor refinement, translation-liberation-
screw- and positional refinement using the programs Phenix [32]
and Autobuster [34]. The final R-factors of the model are
Rwork = 20.0% and Rfree = 22.6%, respectively.
Using the program CNS [35], cross-validated, sigma-A
weighted 2Fo–Fc composite omit maps were calculated to verify
the accuracy of our structural models. For this we used the
standard CNS protocol with a simulated annealing step from
500 K to 0 K.
According to [24], the elbow angle is defined as the angle
between the pseudo-twofold axes between the light and heavy
chain variable and constant domains, respectively. The elbow
angle is the obtuse angle obtained by taking the arccos of the dot
product of the two vectors. Elbow angles and pseudo-dyad axes
were calculated using the PyMol script provided at http://www.
pymolwiki.org/index.php/Elbow_angle. Intra-protein hydrogen
bonds were detected using the PyMol function ‘‘find_pairs’’ with
default settings. All figures of X-ray structures were prepared with
PyMOL (www.pymol.org).
Thermal stability
Thermal stability was measured using an Optim1000 system
(Avacta Group plc) as the change in intrinsic protein fluorescence
upon excitation at 266 nm. In a micro cuvette array, 9 mL of the
samples in 20 mM Histidine, 140 mM NaCl, pH 6.0 at a
concentration of 1 mg/mL were heated from 40 uC to 90 uC at
a rate of 0.1 uC/min. Fluorescence emission spectra were recorded
every 0.4 uC andprocessed with the software IgorPro, Version 6.23
(Avacta Group plc) in order to obtain the fluorescence emission
peak wavelength. The melting point is defined as the inflection
point of a peak wavelength versus temperature plot.
Target binding assay
Surface Plasmon Resonance (SPR) experiments were performed
on a BiacoreT200 instrument (GE Healthcare) at 25 uC using
HBS-P (10 mM HEPES, 150 mM NaCl, 0.05% P20 pH 7.4) as
running and dilution buffer. Full-length Angiopoietin-2 was
immobilized on the surface of a CM5 sensor chip using standard
amine-coupling chemistry yielding a surface density of approxi-
mately 500 RU. Three independent concentration series of the
Fab and CrossFab, spanning a range between 300 and 3.7 nM,
were injected. Two concentrations in each series were run in
duplicate at the start and the end of a measurement series to proof
surface stability. Association and dissociation time was 3 minutes
with a flow rate of 50 mL/min. A regeneration solution of 10 mM
sodium hydroxide was injected for 1 min at 5 ml/min flow rate to
remove any non-covalently bound protein after each binding
cycle. The experimental curves were fitted globally to a 1:1
Langmuir binding model using the BIAevaluation software. The
reported association, dissociation and affinity constants represent
the average of these triplicate measurements, together with their
standard deviations.
Structure of a CrossFab
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Accession codes
Coordinates and structure factors were deposited at the Protein
Data Bank (PDB) with accession numbers 4IMK (Fab) and 4IML
(CrossFab).
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